12:00 – 12:30 pm PDT – Registration and lunch
12:30 – 1:30 pm PDT – Roundtable discussion
McDermott Will & Emery invites you to an update and discussion of legal developments in the life sciences, biotechnology and pharmaceutical fields.
Our roundtable discussion will include:
- The Supreme Court of the United States’ decision in Association for Molecular Pathology v. Myriad Genetics, Inc. on the question, “Are human genes patentable?” We will discuss whether Myriad’s patents to the BRCA gene cover a "product of nature," and therefore are not eligible for patenting, and the implications of the decision.
- The Supreme Court’s decision in Federal Trade Commission v. Actavis, involving a split among the circuit courts on whether a brand name drug manufacturer acts illegally by paying a competing generic drug manufacturer to stay out of the market for a specific period of time.
- The May 13, 2013, Supreme Court opinion in Bowman v. Monsanto Co. reaffirming the scope of patent protection over seeds, and possibly over other self-replicating technologies. The Supreme Court found that a purchaser of patented seeds may not reproduce them through planting and harvesting without the patent holder’s permission.
- Two 2013 decisions from the U.S. Court of Appeals for the Federal Circuit on “divided infringement” (Aristocrat Technologies Australia Pty. Ltd. v. International Game Technology and Move Inc., et al., v. Real Estate Alliance Ltd.) that provide additional guidance on infringement of patent claims where the claim steps are conducted by more than one actor.
William Gaede, Partner
Judith S.H. Hom, Ph.D., Of Counsel
Judy Mohr, Ph.D., Partner
Bhanu K. Sadasivan, Ph.D., Partner
For more information, please contact Nicholas T. Latham.
CLE credit is pending in California, Illinois, New York and Texas. A Uniform Certificate of Attendance will be made available to participants requesting CLE credit in all other states.
McDermott Will & Emery's IP Management Roundtables are designed for the educational benefit of a company president, CEO, general counsel or other executive with an interest in intellectual property. Please be advised McDermott has the right to restrict attendance and may limit participation in this event.